Watson's Gelnique cleared by FDA for overactive bladder

01/29/2009 | WebMD

The FDA approved Watson Pharmaceuticals' Gelnique to treat an overactive bladder. The gel is intended to avert adverse reactions linked to other versions of oxybutynin, the product's active ingredient. The company expects to launch Gelnique as a prescription medication in the second quarter of this year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care